Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
From KEDI Global Longevity Bio Index (KGLB)
4/29/2026, 12:00:00 AM
Regeneron will report its first quarter 2026 financial and operating results on April 29, 2026, before the U.S. financial markets open. The earnings release is estimated to have a medium impact (5-10%) based on historical price volatility, and this event is scheduled.
Korean Translation
2026년 4월 29일, 리제네론은 미국 금융 시장 개장 전에 2026년 1분기 재무 및 운영 실적을 발표할 예정임. 실적 발표에 따른 통상적인 변동성을 고려할 때 중간 정도의 영향(5-10%)을 미칠 것으로 예상되며, 본 이벤트는 예정됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM